BioPorto A/S

Copenhagen Stock Exchange BIOPOR.CO

BioPorto A/S Shares (Diluted, Weighted) for the year ending December 31, 2023: 358,498,000

BioPorto A/S Shares (Diluted, Weighted) is 358,498,000 for the year ending December 31, 2023, a 8.24% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

BioPorto A/S Shares (Diluted, Weighted) for the year ending December 31, 2022 was 331,201,679, a 19.12% change year over year.
BioPorto A/S Shares (Diluted, Weighted) for the year ending December 31, 2021 was 278,051,951, a 30.21% change year over year.
BioPorto A/S Shares (Diluted, Weighted) for the year ending December 31, 2020 was 213,540,921, a -16.41% change year over year.
BioPorto A/S Shares (Diluted, Weighted) for the year ending December 31, 2019 was 255,465,806, a 29.52% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

Copenhagen Stock Exchange: BIOPOR.CO

BioPorto A/S

CEO	Mr. Peter Moerch Eriksen B.B.A., BBA
IPO Date	Jan. 13, 2000
Location	Denmark
Headquarters	Tuborg Havnevej 15, st.
Employees	27
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.

Key trends

Past 5 years